Histogen and Amerimmune Announce First Patient Dosed in Phase 1 Study of Emricasan in Symptomatic COVID-19 Patients

Yesterday, Histogen and Amerimmune, a research center and immunology laboratory owned by CIIC Member Dr. Oral Alpan, announced dosing the first patient in a Phase 1 study of Emricasan in mild symptomatic -COVID-19 patients to assess safety, tolerability, and preliminary efficacy.

SUNY Downstate Medical Center in Brooklyn, New York, has been selected as the single site for the study conduct.

Link to Publication

About Ammerimmune

Amerimmune LLC is a research center and immunology laboratory with a strong focus on identifying underlying mechanisms of immune disorders. Amerimmune’s mission is to bring relevant science, data, and diagnostic and therapeutic solutions to diseases that involve the immune systemAmerimmune LLC is a spinoff of Amerimmune Diagnostics LLC, which is focused on establishing a network of physician-owned immunology labs across the United States. Amerimmune Diagnostics’ clinical approach led to the development of the innovative therapeutics technology upon which Amerimmune was founded. When the COVID-19 pandemic emerged early this year, Amerimmune brought its expertise to bear against this devastating disease. Amerimmune is a privately held development-stage company based in Fairfax, VA. For more information and to explore partnering opportunities, please visit www.amerimmune.com.

About the CIIC

The CIIC is a professional medical organization formed in 2013 and comprised of select Board Certified Immunologists in private practice throughout the USA. We provide high quality care for patients with Primary Immune Deficiency Disorders (PIDD), promote access to treatment, serve as advocates to patients and physicians who care for PIDD patients and participate in research that benefits patient care.

CIIC Mission – Provide cutting edge therapy to patients with Primary Immune Deficiency


Lyn Lewars


[email protected]